Alert detail
LCD L40187 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Palmetto GBA
What changed
Who’s affected: Clinical Laboratory billing teams · Effective: August 10, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 12 billing codes.
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Audit documentation
Building an audit file?
The Tripwire Audit Pack exports 12 months of Clinical Laboratory policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Not ready to subscribe?
Get the free weekly reimbursement brief for Clinical Laboratory— the week’s changes and deadlines, delivered to your inbox. No account required.